Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients stratified by race

被引：0
|
作者：
Cohen, A. [1 ]
Sah, J. [2 ]
Dhamane, A. [3 ]
Lee, T. [4 ]
Rosenblatt, L. [3 ]
Hlavacek, P. [4 ]
Emir, B. [4 ]
Keshishian, A. [2 ]
Yuce, H. [5 ]
Luo, X. [6 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust London, Kings Coll London, Dept Med Hematol, London, England
[2] STATinMED Res, Ann Arbor, MI USA
[3] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[4] Pfizer Inc, New York, NY USA
[5] CUNY, New York City Coll Technol, New York, NY 10021 USA
[6] Pfizer Inc, Groton, CT USA
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1940 / 1940
页数：1
相关论文
共 50 条
  • [31] A Comparison of Bleeding Events Among Patients on Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism
    Schaefer, Jordan K.
    Errickson, Josh
    Kong, Xiaowen
    Ali, Mona A.
    Chipalkatti, Naina
    Haymart, Brian
    Kaatz, Scott
    Krol, Gregory D.
    Sood, Suman L.
    Froehlich, James
    Barnes, Geoffrey D.
    [J]. BLOOD, 2023, 142
  • [32] Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight
    Wysokinski, Waldemar E.
    Froehling, David A.
    Houghton, Damon E.
    McBane, Robert D.
    Vlazny, Danielle T.
    Bott-Kitslaar, Dalene M.
    Kuczmik, Wiktoria
    Sutkowska, Karolina
    Bator, Kaja
    Hodge, David O.
    Peterson, Lisa G.
    Casanegra, Ana, I
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (04) : 484 - 494
  • [33] Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study
    Fukasawa, Toshiki
    Seki, Tomotsugu
    Nakashima, Masayuki
    Kawakami, Koji
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (09) : 2083 - 2097
  • [34] Comparative safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism - a Danish nationwide study
    Sindet-Pedersen, C.
    Staerk, L.
    Pallisgaard, J. Langtved
    Gerds, T. Alexander
    Berger, J. S.
    Torp-Pedersen, C.
    Gislason, G.
    Olesen, J. Bjerring
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 1035 - 1035
  • [35] Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism
    DeLoughery, Thomas
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 159 (08)
  • [36] APIXABAN AND RIVAROXABAN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN OBESE PATIENTS
    Kafka, Wesley
    Cook, Stephen
    Ferris, Jessica
    Hill, Sharon
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [37] Safety and effectiveness of apixaban compared to warfarin in dialysis patients
    Reed, Daniel
    Palkimas, Surabhi
    Hockman, Rebecca
    Abraham, Sumner
    Le, Tri
    Maitland, Hillary
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2018, 2 (02) : 291 - 298
  • [38] The comparative effectiveness and safety of warfarin, rivaroxaban, and apixaban in patients with venous thromboembolism: An analysis of three real-world US healthcare databases
    Iyer, Geetha
    Tesfaye, Helen
    Brill, Gregory
    Zakoul, Heidi
    Schneeweiss, Sebastian
    Bykov, Katsiaryna
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 11 - 12
  • [39] Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study
    Ellenbogen, Michael, I
    Ardeshirrouhanifard, Shirin
    Segal, Jodi B.
    Streiff, Michael B.
    Deitelzweig, Steven B.
    Brotman, Daniel J.
    [J]. JOURNAL OF HOSPITAL MEDICINE, 2022, 17 (10) : 809 - 818
  • [40] Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs
    Spyropoulos, Alex C.
    Ashton, Veronica
    Chen, Yen-Wen
    Wu, Bingcao
    Peterson, Eric D.
    [J]. THROMBOSIS RESEARCH, 2019, 182 : 159 - 166
12345